Q3 2016 13F Holders as of 9/30/2016
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
76.2M
-
Number of holders
-
30
-
Total shares
-
9.93M
-
Shares change
-
+4.57M
-
Total reported value, excl. options
-
$80.2M
-
Value change
-
+$36.8M
-
Number of buys
-
18
-
Number of sells
-
-4
-
Price
-
$8.10
Significant Holders of Xenon Pharmaceuticals Inc. - COMMON STOCK (XENE) as of Q3 2016
30 filings reported holding XENE - Xenon Pharmaceuticals Inc. - COMMON STOCK as of Q3 2016.
Xenon Pharmaceuticals Inc. - COMMON STOCK (XENE) has 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.93M shares
of 76.2M outstanding shares and own 13.02% of the company stock.
Largest 10 shareholders include BVF INC/IL (3.11M shares), Capital World Investors (1.03M shares), ORBIMED ADVISORS LLC (1M shares), PERCEPTIVE ADVISORS LLC (763K shares), Tekla Capital Management LLC (700K shares), DAFNA Capital Management LLC (514K shares), Invesco Private Capital, Inc. (412K shares), Opaleye Management Inc. (410K shares), ROYAL BANK OF CANADA (367K shares), and Point72 Asset Management, L.P. (359K shares).
This table shows the top 30 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.